1562406-27-2

Basic information

• Product Name: C₂₅H₂₇F₂N₄O₈P
• CAS NO: 1562406-27-2
• Molecular Weight: 580.482
• Mol File: 1562406-27-2.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: C₂₅H₂₇F₂N₄O₈P(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₅H₂₇F₂N₄O₈P(1562406-27-2)
• EPA Substance Registry System: C₂₅H₂₇F₂N₄O₈P(1562406-27-2)

Safety Data

• Hazardous Substances Data: 1562406-27-2(Hazardous Substances Data)

Upstream product

• 183370-70-9 phenyl(benzyloxy-L-alaninyl)phosphorochloridate 
• 250698-51-2 (2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4,4-difluoro-2-(hydroxymethyl)tetrahydrofuran-3-yl tert-butyl carbonate 
• 95058-81-4 gemcitabine 
• 770-12-7 O-phenyl phosphorodichloridate 
• 5557-81-3 L-alanine benzyl ester hydrochloride 
• 5557-81-3 alanine benzyl ester hydrochloride 
• 688009-09-8 4-amino-1-((2R,4R,5R)-4-((tert-butyldimethylsilyl)oxy)-5-(((tert-butyldimethylsilyl)oxy)methyl)-3,3-difluoro-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one 
• 1147182-15-7 (2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4,4-difluoro-2-(hydroxymethyl)tetrahydrofuran-3-yl benzoate hydrochloride 
• 840506-29-8 (2S)-benzyl 2-(((RS)-(((2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4,4-difluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate 

Relevant articles and documents

Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem CellsIn Vitro

A 3′-protected route toward the synthesis of the diastereomers of clinically active ProTides, NUC-1031 and NUC-3373, is described. Thein vitrocytotoxic activities of the individual diastereomers were found to be similar to their diastereomeric mixtures. In the KG1a cell line, NUC-1031 and NUC-3373 have preferential cytotoxic effects on leukemic stem cells (LSCs). These effects were not diastereomer-specific and were not observed with the parental nucleoside analogues gemcitabine and FUDR, respectively. In addition, NUC-1031 preferentially targeted LSCs in primary AML samples and cancer stem cells in the prostate cancer cell line, LNCaP. Although the mechanism for this remains incompletely resolved, NUC-1031-treated cells showed increased levels of triphosphate in both LSC and bulk tumor fractions. As ProTides are not dependent on nucleoside transporters, it seems possible that the LSC targeting observed with ProTides may be caused, at least in part, by preferential accumulation of metabolized nucleos(t)ide analogues.

Phenylalanine amidated nucleotide derivative and preparation method and application thereof

The invention provides a phenylalanine amidated nucleotide derivative and a preparation method and application thereof. Halogenated phenylalanine is combined with amino of an amino-containing nucleoside compound while phosphorylation is performed; through a monophosphate synthesis link for promoting absorption and avoiding speed limiting in a form of phosphate and phosphamide prodrug, action of nucleoside deaminase is reduced or avoided to enhance efficacy; halogenated phenylalanine has synergistic effect in inhibiting protein synthesis, thereby playing a role in improving bioavailability andefficacy and reducing drug tolerance in the antitumor and anti-HBV aspects.